---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-068546"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:14:44.859002+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025

## Summary
- Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.
- Cash of $216.7M; runway extended into Q1 2027 via reduction in preclinical spend and headcount.
- TNG462 Phase 1/2 monotherapy data update expected 2H 2025; registrational study in pancreatic cancer planned for 2026.
- Combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors daraxonrasib and zoldonrasib to begin enrollment Q2 2025.
- TNG456 Phase 1/2 trial for glioblastoma enrollment expected Q2 2025; TNG260 clinical data update expected 2H 2025.

## SEC filing metadata
- accession: 0000950170-25-068546
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/0000950170-25-068546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017025068546/tngx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-068546
- JSON: https://secwatch.observer/filing/0000950170-25-068546.json
- Plain text: https://secwatch.observer/filing/0000950170-25-068546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.